

Invitation

beyond  
glaucoma 2021



We invite you to join us for  
**beyond glaucoma 2021:**

**Time for glaucoma – Are we  
seeing clinical practice clearly?**



**Friday 24th September**  
15:00-18:30 CET



**Saturday 25th September**  
10:00-12:30 CET

Accreditation has been requested from NOG



Register here:  
[registerbeyond.allergan.com](https://registerbeyond.allergan.com)

**beyond**  
glaucoma **virtual**

**Privacy Policy**

Your privacy is important to us. Allergan will treat personal information provided at registration for this meeting as confidential and will hold your personal information in compliance with the applicable data protection laws. All faculty are paid consultants to Allergan, an AbbVie company. Content produced in accordance with UK product labels.

These presentations are the property of the speaker and must not be recorded.

# Meet the Experts

**Ike Ahmed** – Canada

**David Crabb** – UK

**Jonathan Crowston** – Singapore

**Antonio Fea** – Italy

**Francisco Goñi** – Spain

**Paul Harasymowycz** – Canada

**Nathan Kerr** – Australia

**Anthony Khawaja** – UK

**Marta Pazos** – Spain

**Herbert Reitsamer** – Austria

**Ingeborg Stalmans** – Belgium

**Yi Xing** – China



# Programme **Friday 24th September**

## 15.00-18.30 CET

(FROM FRIDAY 24TH SEPTEMBER 15:00)

VIRTUAL PLATFORM IS OPEN FOR VIEWING RESOURCES AND PRE RECORDED CONTENT

16:00 -16:07 (7 mins)	<b>Beyond 2021: Welcome and Introduction</b>	Ingeborg Stalmans, MD (Belgium) – Chair Jonathan Crowston, MD (Singapore) – Chair
16:07-16:27 10 mins presentation / 10 mins Q&A (moderated by chairs)	<b>PLENARY: Current challenges in glaucoma</b>	Jonathan Crowston, MD
16:27-16:47 10 mins / 10 mins Q&A (moderated by chairs)	<b>Living with glaucoma: Visual disability and quality of life</b>	Prof David Crabb, Ph.D. Vision Science (UK)
<b>2020 EGS Guidelines</b>	<b>The impact on medical and surgical management of primary open angle glaucoma Part I: Medical management &amp; SLT in depth</b>	Moderated by Jonathan Crowston, MD
16:47-16:58 (11 mins)	<b>A closer look: The latest EGS therapeutic algorithm</b>	Anthony Khawaja, MD (UK)
16:58-17:06 (8 mins)	<b>A closer look: Are we achieving the most with medical treatment in early glaucoma ?</b>	Francisco Goñi , MD (Spain)
17:06-17:17 (11 mins)	<b>Q&amp;A session</b>	All
17:17-17:25 (7 mins)	<b>BREAK</b>	
<b>2020 EGS Guidelines</b>	<b>The impact on medical and surgical management of primary open angle glaucoma Part II: Glaucoma surgery in depth</b>	Moderated by Ingeborg Stalmans, MD & Herbert Reitsamer, MD
17:25-17:33 (8 mins)	<b>The optimal union of the right patient at the right time</b>	Marta Pazos , MD (Spain)
17:33-17:45 (8 mins)	<b>Pearls and pitfalls for an Ab Interno approach</b>	Antonio Fea , MD (Italy)
17:45-18:00 (15 mins)	<b>Ten tips to optimise an Ab Interno approach</b>	Ike Ahmed, MD (Canada)
18:00-18:25 (15 mins)	<b>Q&amp;A session</b>	Moderated by Ingeborg Stalmans, MD & Herbert Reitsamer, MD
18:25-18:30 (5 mins)	<b>Conclusions</b>	Chairs
18:45-19:00 (15 mins Q&A)	<b>XEN 45 in the clinic – A session of case studies</b>	Paul Harasymowycz , MD (Canada)
<b>On Demand Video</b>	<b>Meet the researcher: ‘Primary needling of the Ab Interno gelatin microstent reduces postoperative needling and follow up requirements’</b>	Nathan Kerr, MD (Australia)
<b>On demand video</b>	<b>What does the evidence say?: ‘The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open angle glaucoma and ocular hypertension: A systematic review and meta analysis’</b>	Yi Xing, MD (China)

XEN is a class III medical device CE 2797

This meeting for health care professionals contains educational and promotional material.

Meeting organised and funded by Allergan – an AbbVie Company

NL-NON-2150027 | August 2021



**Register here:**  
[registerbeyond.allergan.com](https://registerbeyond.allergan.com)

# Programme **Saturday 25th September**

**10:00-12:30 CET**

(FROM FRIDAY 24TH SEPTEMBER 15:00)

VIRTUAL PLATFORM IS OPEN FOR VIEWING RESOURCES AND PRE RECORDED CONTENT

<b>10:00-10:07</b> (7 mins)	<b>Beyond 2021: Welcome and Introduction</b>	Ingeborg Stalmans, MD (Belgium) Chair Jonathan Crowston, MD (Singapore) Chair
<b>10:07-10:27</b> 10 mins presentation / 10 mins Q&A (moderated by chairs)	<b>PLENARY: Current challenges in glaucoma</b>	Jonathan Crowston, MD
<b>10:27-10:47</b> 10 mins /10 mins Q&A (moderated by chairs)	<b>Living with glaucoma: Visual disability and quality of life</b>	Prof David Crabb, Ph.D. Vision Science (UK)
<b>2020 EGS Guidelines</b>	<b>The impact on medical and surgical management of primary open angle glaucoma Part I: Medical management &amp; SLT in depth</b>	Moderated by Jonathan Crowston , MD
<b>10:47-10:58</b> (11 mins)	<b>A closer look: The latest EGS therapeutic algorithm</b>	Anthony Khawaja, MD (UK)
<b>10:58-11:06</b> (8 mins)	<b>A closer look: Are we achieving the most with medical treatment in early glaucoma ?</b>	Francisco Goñi , MD (Spain)
<b>17:06-17:17</b> (11 mins)	<b>Q&amp;A session</b>	All
<b>17:17-17:25</b> (7 mins)	<b>BREAK</b>	
<b>2020 EGS Guidelines</b>	<b>The impact on medical and surgical management of primary open angle glaucoma Part II: Glaucoma surgery in depth</b>	Moderated by Ingeborg Stalmans, MD & Herbert Reitsamer, MD (Austria)
<b>11:25-11:33</b> (8 mins)	<b>The optimal union of the right patient at the right time</b>	Marta Pazos , MD (Spain)
<b>11:33-11:45</b> (8 mins)	<b>Pearls and pitfalls for an Ab Interno approach</b>	Antonio Fea , MD (Italy)
<b>11:45-12:00</b> (15 mins)	<b>Ten tips to optimise an Ab Interno approach</b>	Ike Ahmed, MD (Canada)
<b>12:00-12:25</b> (25 mins)	<b>Q&amp;A session</b>	Moderated by Ingeborg Stalmans, MD & Herbert Reitsamer, MD
<b>12:25-12:30</b> (5mins)	<b>Conclusions</b>	Chairs
<b>12:45-13:00</b> (15 mins)	<b>XEN 45 in the clinic – A session of case studies</b>	Paul Harasymowycz , MD (Canada)
<b>On demand video</b>	<b>Meet the researcher: ‘Primary needling of the Ab Interno gelatin microstent reduces postoperative needling and follow up requirements’</b>	Nathan Kerr, MD (Australia)
<b>On demand video</b>	<b>What does the evidence say?: ‘The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open angle glaucoma and ocular hypertension: A systematic review and meta analysis’</b>	Yi Xing, MD (China)

**Virtual platform closes at 14:00 CET**

(viewing pre recorded content no longer possible)



**Register here:**  
[registerbeyond.allergan.com](https://registerbeyond.allergan.com)